Can Orforglipron Cause Gallbladder Problems?

What does the Foundayo label say about the gallbladder?

Foundayo is orforglipron, an oral, once-daily GLP-1 receptor agonist approved in April 2026 for weight reduction and long-term weight maintenance in adults with obesity, or with overweight plus a weight-related condition; its label carries no diabetes indication [1][3].

Under Warnings and Precautions, the label has a section headed Acute Gallbladder Disease: the reaction has been reported in clinical trials, and if cholecystitis is suspected, gallbladder studies and clinical follow-up are indicated [1]. Acute gallbladder disease also appears in the label's list of serious adverse reactions at the front of the Adverse Reactions section [1].

How often did gallbladder problems occur in the trials?

The gallbladder figures come from the pooled safety data of Trials 1 and 2, two randomized, double-blind, placebo-controlled weight-management trials of up to 72 weeks that together included 3,155 adults treated with orforglipron and 1,576 on placebo [1].

In that pool, cholelithiasis (gallstones) was reported in 1% of orforglipron-treated patients and 0.7% of placebo-treated patients, and acute cholecystitis was reported in 0.4% of orforglipron-treated patients and 0.3% of placebo-treated patients [1]. The absolute gap for gallstones is roughly a third of one percentage point.

In the same trials, digestive side effects were more frequently reported. At the 17.2 mg dose, nausea was reported in 35% of patients versus 10% on placebo [1]. The gallbladder figures are pooled across doses [1].

How common are gallstones in the general population?

An estimated 10% to 15% of adults in Europe and the US have gallstones [2]. That is a prevalence figure; the trial percentages above count gallstones reported during up to 72 weeks of treatment, so the two are not directly comparable.

What does the Wegovy label say about weight loss and gallstones?

The Wegovy (semaglutide) label, a different product, states that substantial or rapid weight loss can increase the risk of cholelithiasis, and that acute gallbladder disease was still more frequent in Wegovy-treated patients than in placebo-treated patients even after accounting for the degree of weight loss [4].

What does the label say about severe stomach pain?

Suspected cholecystitis calls for gallbladder studies and clinical follow-up, per the label [1]. The label also carries a separate warning for acute pancreatitis, which can cause persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting; the label says to discontinue Foundayo if pancreatitis is suspected [1].

Can ursodiol prevent gallstones during orforglipron treatment?

The ursodiol evidence cited here comes from a gastric bypass trial of ursodiol during weight loss after surgery, not from people taking orforglipron: among 233 patients with at least one follow-up ultrasound, gallstones at 6 months formed in 32% of those on placebo, 13% on ursodiol 300 mg daily, 2% on 600 mg daily and 6% on 1,200 mg daily, with the 600 and 1,200 mg doses significantly lower than placebo (P<0.001) [5].

Is the risk the same as with other GLP-1 drugs?

Acute gallbladder disease is a labeled warning for GLP-1 medicines generally, and the numbers differ by product and trial. The Wegovy (semaglutide) label reports cholelithiasis in 1.6% of semaglutide injection-treated adults versus 0.7% on placebo, and cholecystitis in 0.6% versus 0.2%, in randomized weight-reduction trials [4]. Orforglipron's pooled rates were 1% versus 0.7% for gallstones and 0.4% versus 0.3% for cholecystitis [1].

Those figures should not be read as a head-to-head comparison. Response rates from separate trials, run in different populations with different designs, cannot be compared directly, as the labels themselves note [4][1].